GOSS — Gossamer Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1728117 ·
Last close
$11.04
Market Cap
$67.52M
52W High
$309.60
52W Low
$8.29
ADV30
201,114
Next earnings
2026-11-10
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 38,431,000 — 9,966,000 -48,072,000 64,337,000 51,189,000 187,132,000
Jun 2026 9,238,000 — -26,074,000 16,900,000 76,867,000 41,148,000 170,896,000
Mar 2026 16,955,000 — -44,866,000 -46,664,000 128,899,000 41,028,000 290,382,000
Dec 2025 13,799,000 — -46,040,000 -47,238,000 172,249,000 37,732,000 295,009,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-156,038,000
Investing CF
$173,362,000
Financing CF
$25,042,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-46.56
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,516,774,000
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-114,487,000
Pretax Income TTM
$-125,162,000
Interest Exp TTM
$10,675,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$78,423,000
EBITDA
$-106,996,000
Free Cash Flow
$-29,764,624
Enterprise Value
$48,608,568
Total Cash
$57,026,000
Total Debt
$40,068,000
Shares Out
6,116,390
Trailing EPS
$-41.48
Book Value
$-42.03
ROE
—
ROA
-62.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 48,471,000 -163,253,000 -170,370,000 172,249,000 295,009,000 -122,760,000 -171,266,000
Dec 2024 114,701,000 -59,919,000 -56,528,000 315,292,000 285,800,000 29,492,000 -3,468,000
Dec 2023 0 -173,759,000 -179,817,000 311,916,000 249,147,000 62,769,000 -159,158,000
Dec 2022 0 -218,528,000 -229,378,000 272,450,000 260,373,000 12,077,000 -187,032,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$53,286,000
NetIncome TTM
$-125,223,000
OpCashFlow TTM
—
Assets (Latest)
$76,867,000
Forward EPS
$-10.32

Max Pain — expiry 2028-01-21

max pain strike: $7.00 · spot: $11.43 · call oi: 3,492 · put oi: 0
Expected Move to 2028-01-21: ±$6.93 (60.63%) — implied range $4.50 – $18.36 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CING Cingulate Inc. $68.64M $4.72 —
MNOV MEDICINOVA INC $68.65M $1.34 —
KALA KALA BIO, Inc. $66.34M $3.43 —
VTVT vTv Therapeutics Inc. $69.36M $17.29 —
TENX TENAX THERAPEUTICS, INC. $64.66M $1.42 —

News headlines (Yahoo Finance, 1h cache)

Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect?
2026-11-17 13:55 · Yahoo
Gossamer Bio: Q3 Earnings Snapshot
2026-11-10 21:11 · Yahoo
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-10 21:01 · Yahoo
Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks
2026-10-17 03:20 · Yahoo
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
2026-10-01 23:12 · Yahoo
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
2026-09-23 20:01 · Yahoo
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
2026-09-11 12:00 · Yahoo
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
2026-09-08 08:31 · Yahoo
Gossamer Bio to Present at Cantor Global Healthcare Conference
2026-09-04 12:00 · Yahoo
Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
2026-08-27 19:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.